



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 09/12/2023 10:45 Received: 09/12/2023 10:45

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: NRAS Mutation Analysis, Colon, NOT DETECTED, QCR

Reference Range:
NOT DETECTED

Based on sequencing analysis, no clinically significant mutations were detected in the NRAS gene exons 2-4.

Activating NRAS oncogenic mutations are detected in a wide variety of cancers, including colorectal carcinomas, melanomas and acute myeloid leukemias.

In fixed tissue samples, the area of tumor was grossly macrodissected prior to DNA extraction. Nucleic acid was subjected to Next-generation sequencing of exons 2, 3 and 4 of NRAS gene (NM_002524.4). The sensitivity for mutation detection of the assay is 5% mutant allele in a background of normal alleles. Insertions up to 30bp and deletions up to 48bp have been successfully detected by this assay.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Laboratory results and submitted clinical information reviewed by Bernard Joseph Ilagan, MD, MHA, FACMG, CGMS.
Test Performed at:
Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042 I Maramica MD, PhD, MBA

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

Reported Date: 2023.09.12 10:45 NRMUA

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED